Business Money News Retail State

MedMen pre-announces large sales decline and massive tax bill

Through an SEC filing announcing its inability to file its 10-Q on a timely basis, MedMen (CSE: MMEN) (OTC: MMNFF) disclosed that its financials deteriorated in its fiscal Q2. It suggested that revenue was $33.8 million, which is a decline of 23% from a year ago and below the analyst consensus of $38.8 million. In its fiscal Q1, it reported revenue of $35.6 million. It blamed the weakness on COVID-19’s impact on retail traffic and tourism in California and Nevada. It noted substantial growthin Florida and Illinois compared to a year ago.

MedMen expects its operating loss in Q2 to improve to $42.9 million compared to $69.3 million a year ago, with gross margin improving to 39.9% from 29.1% and SG&A declining by 47.2% from the year-ago quarter. The operating loss is a sharp deterioration from Q1’s $8.1 million.

To Read The Rest Of This Article By Alan Brochstein on New Cannabis Ventures

Published: February 12, 2021

SHARE
RELATED POSTS
California Gov. Jerry Brown Announces Appointments to the Cannabis Control Appeals Panel
The top 7 law firms in cannabis, according to investors, startups and major companies in the booming industry
Man Who Served Longest Sentence in U.S. History for Cannabis to be Released After 39 Years

Leave Your Reply

*